Pembrolizumab (Keytruda®)
Dokument
Fact Sheet
Spezifizierung
Lungenkarzinom, nicht-kleinzellig (NSCLC)
» PD-L1 ≥1%
» ab Zweitlinientherapie
Stand
Juli 2021
Dies ist die aktuell gültige Version des Dokuments
1Pembrolizumab, NSCLC, PD-L1 ≥1%, second line
1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/414 results for control, results for new therapy15 hazard ratio for new therapy16 n. s. not significant29 Pemetrexed, Docetaxel or Nivolumab30 Pemetrexed, Docetaxel or Nivolumab
